EPIQ Capital Group LLC Sells 49,979 Shares of Cyclo Therapeutics, Inc. (NASDAQ:CYTH)

EPIQ Capital Group LLC trimmed its position in shares of Cyclo Therapeutics, Inc. (NASDAQ:CYTH) by 6.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 689,447 shares of the company’s stock after selling 49,979 shares during the period. EPIQ Capital Group LLC’s holdings in Cyclo Therapeutics were worth $407,000 at the end of the most recent reporting period.

Cyclo Therapeutics Stock Performance

Shares of Cyclo Therapeutics stock opened at $0.74 on Monday. The company has a fifty day moving average of $0.79 and a 200 day moving average of $0.73. The company has a market capitalization of $24.23 million, a P/E ratio of -0.82 and a beta of -0.57. Cyclo Therapeutics, Inc. has a fifty-two week low of $0.55 and a fifty-two week high of $1.79.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.